Clinical trials: Insulin, completed
Diabetes Type 1
Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump
The current study focuses on terms of use of Insulin Aspart, fast analogue of human insulin and commonly used in the treatment of type 1 diabetes, where it obtained the marketing authorization for this indication.
- Trial name
- BOLUS (NCT02546401)
- Testing
- Insulin Aspart
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Brest
Type 2 Diabetes Mellitus
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart…
- Trial name
- NCT05417841
- Testing
- Insulin Degludec and Insulin Aspart Injection, Insulin Aspart Injection
- Where
- 7 sites in China
- Volunteers
- 218 people
- Sponsor
- Beijing Hospital
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look…
- Trial name
- NCT05013229
- Testing
- IcoSema, Insulin glargine, insulin aspart
- Where
- 182 sites in United States, Czechia and 12 more
- Volunteers
- 679 people
- Sponsor
- Novo Nordisk A/S
Gestational Diabetes Mellitus
Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus
This is a randomized controlled trial of different glycemic targets during tratment of women with GDM with assessement of epygenetic aspects of their effects on the fetus and pregnancy outcomes.
- Trial name
- GEM GDM (NCT03610178)
- Testing
- Very tight glycemic targets, life-style modification, insulin therapy if needed, Tight-moderate glycemic targets, life-style modification, insulin therapy if needed
- Where
- Russia
- Volunteers
- 850 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Diabetes Mellitus, Type 1
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
The aim of the study is to compare the impact of two different insulin dose calculation on postprandial glycemia after mixed meal in children with type 1 diabetes mellitus.
- Trial name
- NCT04124302
- Testing
- Insulin Glulisine, Insulin Aspart, Insulin Lispro
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Medical University of Warsaw
Diabetes Mellitus, Type 1
Tandem Freedom Feasibility Study 1
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a 1 week run-in, then…
- Trial name
- NCT06428591
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes, Type 2 Diabetes
Automated Insulin Delivery for Inpatients With Dysglycemia
This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general…
- Trial name
- AIDING (NCT06418880)
- Testing
- AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Emory University
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Cognitive Impairment
Study of Nasal Insulin to Fight Forgetfulness - Device Study
The SNIFF Device study will involve using a device to administer insulin through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body.
- Trial name
- NCT03857321
- Testing
- Insulin, intranasal nebulizer-like device
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
This study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin.
- Trial name
- NCT04029480
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Insulin
- Where
- 104 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis-related Diabetes
Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin…
- Trial name
- NCT04533646
- Testing
- Insulin, Continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jagdeesh Ullal
Type 1 Diabetes
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
- Trial name
- SUCCEED2 (NCT06604871)
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Medtronic MiniMed, Inc.
type1diabetes
Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.
The goal of this 14-day randomized pilot trial is to assess the accuracy of a continuous ketone monitoring (CKM) system when compared to standard point-of-care capillary ketone monitors in individuals with type 1 diabetes on…
- Trial name
- CKM 1 (NCT06420518)
- Testing
- Ketogenic diets, 8-hour insulin-suspension period
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- McGill University
Type 1 Diabetes
A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes
Primary Objective: To demonstrate bioequivalence between insulin lispro given as SAR342434, 200 Units/ml test formulation (T) and insulin lispro 100 Units/ml reference formulation (R) after a single subcutaneous (SC) dose…
- Trial name
- NCT03903016
- Testing
- Insulin Lispro SAR342434
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).
- Trial name
- NCT05413369
- Testing
- Insulin glargine/Lixisenatide, IDegAsp, Metformin
- Where
- 60 sites in China
- Volunteers
- 582 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Primary Objective: To evaluate the safety of Gla-300 in insulin naïve T2D participants uncontrolled on oral antihyperglycemic drugs Secondary Objective: To assess the efficacy of Gla-300 on glycemic control in insulin naïve T2D…
- Trial name
- SAFEGUARD (NCT04980027)
- Testing
- Insulin glargine (U300)
- Where
- 2 sites in India
- Volunteers
- 228 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to…
- Trial name
- INITIATION (NCT05002933)
- Testing
- Insulin glargine 300 U/ml
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Dexcom Hybrid Closed Loop Insulin Pump Study in Type 1 Diabetes
Treatment of Type 1 diabetes requires daily insulin therapy given by either multiple daily injections or by continuous infusion via a pump.
- Trial name
- NCT05059860
- Testing
- Tandem Control IQ Hybrid Closed Loop Insulin Delivery System
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- NHS Lothian
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes…
- Trial name
- Soli-CGM (NCT05114590)
- Testing
- Insulin glargine/Lixisenatide
- Where
- 18 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sanofi